Citric Acid Metabolism in Resistant Hypertension
Authors:
- Marta Martin-LorenzoMarta Martin-Lorenzo
- Paula J. MartinezPMPaula J. Martinez
- Montserrat Baldan-MartinMBMontserrat Baldan-Martin
- Gema Ruiz-HurtadoGRGema Ruiz-Hurtado
- Julian SeguraJSJulian Segura
- Fernando de la CuestaFernando de la Cuesta
- Maria G. BarderasMaria G. Barderas
- Luis Miguel RuilopeLRLuis Miguel Ruilope
- Gloria Alvarez-LlamasGloria Alvarez-Llamas
- 1 November 2017
- journal article
- research article
- Published by Wolters Kluwer Health in Hypertension
- Vol. 70 (5) , 1049-1056
Abstract
Resistant hypertension (RH) affects 9% to 12% of hypertensive adults. Prolonged exposure to suboptimal blood pressure control results in end-organ damage and cardiovascular risk. Spironolactone is the most effective drug for treatment, but not all patients respond and side effects are not negligible. Little is known on the mechanisms responsible for RH. We aimed to identify metabolic alterations in urine. In addition, a potential capacity of metabolites to predict response to spironolactone was investigated. Urine was collected from 29 patients with RH and from a group of 13 subjects with pseudo-RH. For patients, samples were collected before and after spironolactone administration and were classified in responders (n=19) and nonresponders (n=10). Nuclear magnetic resonance was applied to identify altered metabolites and pathways. Metabolites were confirmed by liquid chromatography-mass spectrometry. Citric acid cycle was the pathway most significantly altered ( P <0.0001). Metabolic concentrations were quantified and ranged from ng/mL malate to μg/mL citrate. Citrate and oxaloacetate increased in RH versus pseudoresistant. Together with α-ketoglutarate and malate, they were able to discriminate between responders and nonresponders, being the 4 metabolites increased in nonresponders. Combined as a prediction panel, they showed receiver operating characteristiccurve with area under the curve of 0.96. We show that citric acid cycle and deregulation of reactive oxygen species homeostasis control continue its activation after hypertension was developed. A metabolic panel showing alteration before spironolactone treatment and predicting future response of patients is shown. These molecular indicators will contribute optimizing the rate of control of RH patients with spironolactone.Keywords
This publication has 42 references indexed in Scilit:
- Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trialThe Lancet, 2015
- A systems view of type 2 diabetes-associated metabolic perturbations in saliva, blood and urine at different timescales of glycaemic controlDiabetologia, 2015
- KLK1 and ZG16B proteins and arginine–proline metabolism identified as novel targets to monitor atherosclerosis, acute coronary syndrome and recoveryMetabolomics, 2014
- A guide for easy- and difficult-to-treat hypertensionInternational Journal of Cardiology, 2014
- Resistant hypertension—its identification and epidemiologyNature Reviews Nephrology, 2012
- Metabolomics and Cardiovascular Biomarker DiscoveryClinical Chemistry, 2012
- Metabolomics in the study of kidney diseasesNature Reviews Nephrology, 2011
- Pathophysiology of Resistant Hypertension: The Role of Sympathetic Nervous SystemInternational Journal of Hypertension, 2011
- Efficacy of Spironolactone Therapy in Patients With True Resistant HypertensionHypertension, 2010
- Resistant Hypertension: Diagnosis, Evaluation, and TreatmentHypertension, 2008